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RanBP2 is a nucleoporinwith SUMOE3 ligase activity
that functions in both nucleocytoplasmic transport
and mitosis. However, the biological relevance of
RanBP2 and the in vivo targets of its E3 ligase activity
are unknown. Here we show that animals with low
amounts of RanBP2 develop severe aneuploidy in
the absence of overt transport defects. The main
chromosome segregation defect in cells from these
mice is anaphase-bridge formation. Topoisomerase
IIa (Topo IIa), which decatenates sister centromeres
prior toanaphaseonset topreventbridges, fails to ac-
cumulate at inner centromeres when RanBP2 levels
are low. We find that RanBP2 sumoylates Topo IIa
in mitosis and that this modification is required
for its proper localization to inner centromeres. Fur-
thermore, mice with low amounts of RanBP2 are
highly sensitive to tumor formation. Together, these
data identify RanBP2 as a chromosomal instability
gene that regulates Topo IIa by sumoylation and
suppresses tumorigenesis.
INTRODUCTION
Most human cancers have an abnormal chromosome content,
a condition known as aneuploidy. However, the molecular de-
fects underlying the development of aneuploidy and its role in
tumorigenesis remain poorly understood (Michor et al., 2005).
Deciphering the molecular networks that regulate the proper
segregation of chromosomes in mitosis is essential to under-
standing the mechanisms that can cause chromosomal instabil-
ity and their role in cancer development. In Saccharomyces
cerevisiae,more than 100 genesare known tocause chromosomal
instability when defective (Kolodner et al., 2002; Nasmyth, 2002).
These genes function in a wide variety of mitotic processes,including chromosome condensation, sister chromatid cohe-
sion, kinetochore assembly, spindle formation, and spindle
assembly checkpoint control. Even more genes are expected
to contribute to chromosomal stability in humans, but only a
limited number have been identified to date (Michor et al., 2005).
Several proteins that mediate transport of macromolecules
into and out of the nucleus through nuclear pores have recently
been implicated in mitosis. One of these proteins is RanBP2 (or
Nup358), a very large multidomain nuclear pore complex protein
that exerts SUMO E3 ligase activity in vitro (Matunis and Pickart,
2005; Pichler et al., 2002; Wu et al., 1995). In interphase cells,
RanBP2 is localized at the cytoplasmic face of the NPC, where
it forms a stable subcomplexwith RanGTPase-activating protein
1 (RanGAP1) and the SUMO E2-conjugating enzyme Ubc9. Only
RanGAP1 conjugated to small ubiquitin-like modifier 1 (SUMO1)
can interact with RanBP2 (Mahajan et al., 1997; Matunis et al.,
1996). Depletion of RanBP2 has no measurable effect on import
of proteins into the nucleus but slightly reduces export of mRNA
and NES-containing proteins from the nucleus, suggesting that
RanBP2 functions as a facilitator of macromolecular export
(Bernad et al., 2004; Hutten and Kehlenbach, 2006). At the onset
of mitosis when the nuclear envelope (NE) disintegrates and
NPCs disassemble, RanBP2-RanGAP1-SUMO1-Ubc9 subcom-
plexes disperse into the mitotic cytosol and accumulate at the
plus ends of free spindle microtubules and at kinetochores of
chromosomes that have been captured by spindle microtubules
(Joseph et al., 2002, 2004). Kinetochore targeting of RanBP2-
RanGAP1-SUMO1-Ubc9 is dependent on the nuclear export
receptor Crm1 (Arnaoutov et al., 2005). In HeLa and RGG cells,
depletion of RanBP2 causes various mitotic abnormalities, in-
cluding misalignment of chromosome in metaphase, mislocali-
zation of several kinetochore-associated proteins, and formation
of multipolar spindles (Joseph et al., 2004; Salina et al., 2003).
The critical biological functions of the mammalian RanBP2
protein have yet to be elucidated. Furthermore, althoughRanBP2
has SUMOE3 ligase activity in vitro, it remains unknownwhether
RanBP2 acts as a SUMO-ligating enzyme in vivo. To address
these issues, we bypassed the problem of embryonic lethalityCell 133, 103–115, April 4, 2008 ª2008 Elsevier Inc. 103
Figure 1. Generation of Mice with Graded Reduction in RanBP2 Dosage
(A) Schematic representation of the RanBP2 gene targeting strategy. The relevant portion of the RanBP2 locus, the targeting vector with loxP (triangles), the
hypomorphic and knockout alleles, and the EcoRV restriction sites (E) and the probe used for Southern blotting are indicated.
(B) (left) Southern blot analysis of RanBP2+/H and RanBP2+/+ mice. (Right) PCR-based genotype analysis of RanBP2 mutant mice.
(C) Western blot analysis of MEFs isolated from mice carrying the indicated RanBP2 alleles using anti-RanBP2 antibody. Actin was used as a loading control.of RanBP2 null mice (Aslanukov et al., 2006) by generating a se-
ries of mutant mice in which the dose of RanBP2 is reduced in
graded fashion. We report here that mice with low amounts
of RanBP2 are viable and overtly indistinguishable from wild-
type mice. We show that there is an inverse correlation between
RanBP2 level of expression and chromosome number instability.
The primemitotic defect associated with RanBP2 insufficiency is
formation of chromatin bridges in anaphase, an abnormality
linked to impaired Topo IIa-mediateddecatenation of sister chro-
matids at anaphase (Clarke et al., 1993). We show that RanBP2
binds to and regulates the sumoylation and localization of Topo
IIa in mitosis. We further show that mice expressing RanBP2 be-
low a threshold level are prone to spontaneous and carcinogen-
induced tumorigenesis.
RESULTS
Generation of Mutant Mice with Low
Amounts of RanBP2
We created a series of mice in which expression of RanBP2 is
reduced in a graded fashion from normal to zero by the use
of various combinations of wild-type (RanBP2+), hypomorphic
(RanBP2H), and knockout (RanBP2) alleles. The RanBP2H allele
was generated by inserting a neomycin resistance cassette into
the third intron of the RanBP2 gene via homologous recombina-
tion (Figures 1A and 1B). The RanBP2 allele was established by
removing exon 3 from the RanBP2H allele via Cre-mediated104 Cell 133, 103–115, April 4, 2008 ª2008 Elsevier Inc.recombination (Figures 1A and 1B). As previously described
(Aslanukov et al., 2006), RanBP2/ mice died during embryo-
genesis. Death occurred prior to day 13.5 of development
(data not shown). In contrast, RanBP2/H and RanBP2H/H mice
were viable and overtly indistinguishable from RanBP2+/,
RanBP2+/H, and RanBP2+/+ mice. Western blot analysis of
mouse embryonic fibroblast (MEF) lysates revealed that
RanBP2+/H, RanBP2+/, RanBP2H/H, and RanBP2/H cells
contained 90%, 44%, 31%, and 26%, respectively, of the
RanBP2 protein level present in RanBP2+/+ MEFs (Figures 1C
and S1).
RanBP2/H Cells Have No Overt
Transport-Related Defects
Next, we investigated whether nucleocytoplasmic transport
might be impaired in RanBP2/H cells. In situ hybridization with
an oligo(dT)50-mer probe revealed that the intracellular distribu-
tion of polyadenylated mRNA was indistinguishable between
RanBP2+/+ and RanBP2/H MEFs, indicating that nuclear export
of bulk mRNA was not affected by decreased RanBP2 expres-
sion (Figure S2A). Furthermore, NLS-mediated protein import
and NES-mediated protein export were both equally efficient in
RanBP2+/+ and RanBP2/H MEFs as measured using estab-
lished in vivo transport assays (Figures S2B–S2E). Collectively,
these results suggest that reduction of RanBP2 protein levels
to about a quarter of normal levels has no overt impact on
nucleocytoplasmic trafficking.
Table 1. Gradual Reduction of RanBP2 Causes Progressively More Aneuploidy in Splenocytes and MEFs
A
Mouse
Age (n)
Mitotic Figures
Inspected
Percent Aneuploid
Figures (SD)
Karyotypes with Indicated Chromosome Number
Mouse
Genotype 35 36 37 38 39 40 41 42 43
RanBP2+/+ 5 mo (4) 200 0 (0) 200
RanBP2+/H 5 mo (3) 150 0 (0) 150
RanBP2+/ 5 mo (3) 150 1 (0) 2 148
RanBP2H/H 5 mo (4) 200 5 (1) 1 6 190 2 1
RanBP2/H 5 mo (4) 200 15 (3) 1 1 4 2 12 170 9 0 1
B
Mitotic Figures
Inspected
Percent
Aneuploid
Figures (SD)
Karyotypes with Indicated Chromosome Number
Mitotic MEF
Genotype (n) 37 38 39 40 41 42 43
RanBP2+/+ (3) 150 9 (2) 4 137 9
RanBP2+/H (3) 150 11 (2) 5 133 8 2 2
RanBP2+/ (3) 150 13 (2) 4 0 3 131 10 0 2
RanBP2H/H (3) 150 26 (2) 2 6 11 111 10 5 5
RanBP2/H (3) 150 33 (2) 3 7 8 100 18 10 4
(A) Analysis of numerical chromosomal abnormalities in splenocytes from 5-month-old mice of the indicated genotypes.
(B) Same analysis as in (A) for P5 MEFs of the indicated genotypes.RanBP2 can sumoylate RanGAP1 in vitro, but whether it does
so in vivo is unclear (Pichler et al., 2002). RanBP2 has further
been proposed to protect SUMO1-modified RanGAP1 from de-
sumoylation by SUMO isopeptidases such as SENP2 (Zhang
et al., 2002). Western blot analysis of RanBP2+/+ and RanBP2/H
MEF lysates for SUMO1 showed that SUMO1-RanGAP1 levels
remained constant in cells with reduced RanBP2 (Figure S2F).
The same holds true for other SUMO1-conjugated proteins and
SUMO2/3-conjugated proteins level (Figure S2G), suggesting
that hypomorphism for the SUMO E3 ligase RanBP2 does not
affect the global patterns of SUMO modification in MEFs.
Mice and MEFs with Low Amounts
of RanBP2 Develop Severe Aneuploidy
To determine whether RanBP2 insufficiency leads to chromo-
somal instability in the context of an adult mouse, we collected
splenocytes from RanBP2+/+, RanBP2+/H, RanBP2+/,
RanBP2H/H, and RanBP2/H mice at 5 months of age and per-
formed karyotype analyses. Chromosome counts showed that
0% of RanBP2+/+ and RanBP2+/H splenocytes were aneuploid
(Table 1A). In contrast, splenocytes from RanBP2+/, RanBP2H/H,
and RanBP2/H mice had 1%, 5%, and 15% incidence of an-
euploidy, respectively, revealing an inverse correlation between
the level of RanBP2 protein and the percentage of aneuploidy
in this cell type. Moreover, the range of abnormal chromosome
numbers broadened substantially with decreasing expression
of RanBP2 protein. The extent of aneuploidy was also deter-
mined in MEFs with graded reduction in RanBP2 expression.
As shown in Table 1B, in passage 5 MEFs, aneuploidy increased
with declining RanBP2 expression levels. These data establish
that RanBP2 is a protein that acts to prevent chromosome
missegregation and accumulation of aneuploid cells.
RanBP2 Insufficiency Induces Anaphase Bridges
To determine the nature of the chromosome missegregation de-
fects underlying the aneuploidy observed in cells with low levelsof RanBP2, the chromosome movements of RanBP2 mutant
MEFs were followed by timelapse live microscopy. To visualize
DNA, MEFs were transduced with a retrovirus expressing
YFP-tagged histone 2B. We found that 9% of RanBP2/H and
RanBP2H/H cells failed to progress frommetaphase to anaphase,
a defect observed in only 2% of RanBP2+/, RanBP2+/H, and
wild-type MEFs (data not shown). Of the RanBP2/H and
RanBP2H/H cells that were able to progress into anaphase,
30% and 28% formed chromatin bridges, respectively (Figures
2A–2C). Most cells had one or two bridges, while a small fraction
of cells had more than two (data not shown). These bridges
resolved in telophase or during cytokinesis (Figure 2A). The per-
centage of chromatin bridges wasmuch lower inRanBP2+/ and
RanBP2+/H anaphases (16% and 12%, respectively) but still sig-
nificantly higher than in RanBP2+/+ anaphases (7%) (Figure 2C).
In addition, a small but statistically significant increase of
centrophilic chromosomes was observed in RanBP2/H and
RanBP2H/HMEFs in comparison toRanBP2+/+MEFs (Figure 2C).
There was a small increase of lagging chromosomes in these
MEFs that did not reach statistical significance (Figure 2C).
Together, the above findings suggest that anaphase-bridge
formation is the main chromosome segregation defect in
RanBP2-insufficient cells.
To examine whether chromatin-bridge formation caused
structural chromosome damage, spectral karyotype (SKY) anal-
ysis was performed on RanBP2/H and RanBP2+/+ MEFs.
Although this analysis confirmed that RanBP2/H cells had
increased numerical chromosome instability, there was no evi-
dence for increased breakage or fusion of chromosome arms
(Figure S3A). Giemsa-stained metaphase spreads from spleno-
cytes and MEFs with various levels of RanBP2 were also
inspected for structural chromosomal abnormalities. Again,
there was no evidence for increased chromosome breakage or
end-to-end fusion in RanBP2 mutant cells, although a small but
significant increase in the incidence of chromosome gaps was
observed in RanBP2H/H and RanBP2/H splenocytes and MEFsCell 133, 103–115, April 4, 2008 ª2008 Elsevier Inc. 105
Figure 2. Cells with Low Levels of RanBP2 Form Chromosome Bridges in Anaphase
(A) Chromosome dynamics and segregation of RanBP2+/+ and RanBP2/HMEFs expressing H2B-YFP were observed by timelapse microscopy. Representative
images of each mitotic stage are shown. Arrowheads mark chromatin bridges in RanBP2/H MEFs. Bar = 10 mm.
(B) High-magnification images of RanBP2/H MEFs with indicated chromosome segregation defects. Bar = 10 mm.
(C) Quantification of the chromosome segregation defects observed by live-cell imaging of MEFs of the indicated genotypes. n = total number of mitotic cells
analyzed from at least three independent MEF lines. Error bars indicate SEM, *p < 0.05 versus wild-type cells (Chi-square test).(Figures S3B–S3D). These data suggest that chromosome-
bridge formation causes aneuploidy in the absence of extensive
structural chromosome damage. However, the possibility that
MEFs with structural damage have reduced viability and thus
go unnoticed cannot be excluded.
Previous studies of HeLa cells have documented that deple-
tion of RanBP2 by RNA interference perturbs mitotic spindle
formation and loading of certain mitotic checkpoint proteins
onto kinetochores in early mitosis (Joseph et al., 2004; Salina
et al., 2003). However, no such mitotic defects were detectable
in RanBP2 hypomorphic MEFs (Figure S4).
Topo IIa Targeting to Inner Centromeres
in Mitosis is Dependent on RanBP2
Formation of chromatin bridges in anaphase is a distinctive fea-
ture of cells in which DNA decatenation is impaired by mutation
or chemical inhibition of Topo IIa (Clarke et al., 1993). Topo IIa is
active in S phase and at the metaphase-anaphase transition,
where it disentangles sister centromeres to enable their separa-
tion in anaphase (Bhat et al., 1996). To examine whether ana-
phase-bridge formation in RanBP2 hypomorphic MEFs might106 Cell 133, 103–115, April 4, 2008 ª2008 Elsevier Inc.be due to Topo IIa insufficiency, we examined lysates from
asynchronous MEF cultures of various RanBP2 genotypes for
Topo IIa expression by immunoblotting. As shown in Figure 3A,
Topo IIa expression levels were independent of RanBP2 status.
RanBP2+/+ and RanBP2/H MEFs that were arrested in mitosis
by nocodazole also contained similar amounts of Topo IIa
(Figure 3B).
Next, we hypothesized that RanBP2 deficiency might cause
anaphase-bridge formation by interfering with proper localization
of Topo IIa to inner centromeres of mitotic chromosomes. To test
for this possibility,RanBP2+/+ andRanBP2/HMEFswere arrested
in prometaphase with monastrol, an inhibitor of the mitotic kinesin
Eg5, and immunostained with anti-Topo IIa and anti-centromeric
antibodies (ACA). We found that Topo IIa concentrated at inner
centromeres inmostRanBP2+/+,RanBP2+/H, andRanBP2+/ cells
(Figures 3C, 3D, and S5). In contrast, the majority of RanBP2H/H
and RanBP2/H MEFs failed to accumulate Topo IIa at inner
centromeres. These results demonstrate that proper targeting
ofTopo IIa to inner centromeresofmitotic chromosomes isdepen-
dent on RanBP2 and suggest that anaphase-bridge formation in
RanBP2 hypomorphic cells is caused by Topo IIamislocalization.
Figure 3. RanBP2 Binds to Topo IIa in Mitosis and Is Essential for Its Accumulation at Inner Centromeres
(A) Western blots of asynchronous MEF lysates probed with antibody to Topo IIa. Actin served as a loading control.
(B) Western blots of synchronized RanBP2+/+ and RanBP2/H MEF lysates. MEFs were synchronized in G0 by serum starvation and then released for the indi-
cated durations in serum-containing medium. Nocodazole was added 23 hr after cells were released. Blots were probed for Topo IIa. Actin was used as loading
control.
(C) Immunolocalization of Topo IIa in MEFs with various levels of RanBP2 during prometaphase. Centromeres were visualized with ACA antibody. DNA was
stained with Hoechst. Magnified images of the centromeric and inner centromeric regions are shown in the insets. Bar = 10 mm.
(D) Quantification of prometaphases with inner centromeric versus diffuse localization of Topo IIa. Seventy-five prometaphases were analyzed per genotype
(three independent MEF lines were analyzed per genotype). Error bars indicate SEM, *p < 0.05 versus wild-type cells (Chi-square test).
(E) Immunoblots of mitotic (M), G1, or G2 HeLa extracts subjected to immunoprecipitation with RanBP2 antibody and analyzed for coprecipitation of Topo IIa.
(F) Immunoblots of mitotic extracts from RanBP2+/+ and RanBP2/H MEFs subjected to immunoprecipitation with RanBP2 antibody and analyzed for coimmu-
noprecipitation of Topo IIa. Phosphohistone H3 (P-H3) signals indicate that similar amounts of mitotic cells were present in the lysates used for immunoprecip-
itation.Cell 133, 103–115, April 4, 2008 ª2008 Elsevier Inc. 107
RanBP2 Binds to Topo IIa in Mitosis
Because Topo IIa localization in mitosis is RanBP2 dependent,
we suspected that the two proteins might form a complex. To in-
vestigate this, RanBP2was immunoprecipitated from interphase
and mitotic HeLa cell extracts and examined for Topo IIa copre-
cipitation. As shown in Figure 3E, about 4%–5% of the cellular
Topo IIa pool coimmunoprecipitated with RanBP2 from mitotic
extracts but not from G1 or G2 extracts. In the reverse
experiment, RanBP2 immunoprecipitated with Topo IIa from
mitotic extracts but again not from interphase extracts (data
not shown). To determine whether the abundance of RanBP2-
Topo IIa complexes in mitosis was affected by RanBP2 insuffi-
ciency, mitotic extracts from RanBP2/H and RanBP2+/+ MEFs
were subjected to coimmunoprecipitation with anti-RanBP2
antibodies. Although Topo IIa coprecipitated with RanBP2 from
RanBP2/H cell extracts, the amount of protein coprecipitated
from RanBP2+/+ cell extracts was considerably greater (Fig-
ure 3F). These data suggest that RanBP2 and Topo IIa form a
complex in mitosis and that RanBP2-insufficient cells have
reduced amounts of this complex. RanBP2 does not colocalize
with Topo IIa at inner centromeres (data not shown). Both
RanBP2andTopo IIa, however, are present in themitotic cytosol,
suggesting that interaction between them takes place in this
subcellular compartment.
The RanBP2 SUMO E3 Ligase Domain Regulates
Proper Chromosome Segregation and Targeting
of Topo IIa to Inner Centromeres
In S. cerevisiae, SUMOmodification of topoisomerase II (Top2p),
which is catalyzed by the E3 ligases Siz1p and Siz2p, targets the
protein to the pericentromeric regions of mitotic chromosomes
(Takahashi et al., 2006). Studies in Xenopus egg extracts and
human cells suggest that Topo IIa is also subjected to sumoyla-
tion in higher eukaryotes (Azuma et al., 2003, 2005; Mao et al.,
2000). Since RanBP2 is a nucleoporin with SUMO E3 ligase ac-
tivity (Pichler et al., 2002), we speculated that this activity might
be required for accumulation of Topo IIa at inner centromeres
and proper separation of sister chromatids. To test this hypoth-
esis, we expressed influenza hemagglutinin (HA) epitope-tagged
RanBP2(2553–2838), a 33 kDa fragment spanning the RanBP2
SUMO E3 ligase domain (Pichler et al., 2004) (Figure 4A),
in RanBP2/H MEFs and measured its ability to correct ana-
phase-bridge formation and Topo IIa localization. Three catalytic
mutants of the SUMO E3 ligase domain, HA-RanBP2(2553–
2838)L2651A,L2653A, HA-RanBP2(2553–2838)F2657A,F2658A, and
HA-RanBP2(2553–2838)L2651A,L2653A,F2657A,F2658A, and two re-
gions flanking the SUMO E3 ligase domain, HA-RanBP2(1950–
2553) and HA-RanBP2(2839–3224), were also expressed in
RanBP2/H cells as controls (Figure 4A). Western blotting for
HA revealed that all RanBP2 fragments were expressed at sim-
ilar levels (Figure S6). Consistent with our earlier results, 28%
of RanBP2/H MEFs expressing empty vector formed anaphase
bridges (Figure 4B). A similarly high percentage of anaphase
bridges was observed in RanBP2/H MEFs expressing the cata-
lytic mutants or the flanking regions of the RanBP2 SUMO E3
ligase domain. By contrast, only 11% of RanBP2/H MEFs
expressing the fully functional RanBP2 SUMO E3 ligase domain
(2553–2838) formed anaphase bridges, a percentage that was108 Cell 133, 103–115, April 4, 2008 ª2008 Elsevier Inc.similar to that recorded forRanBP2+/+ cells expressing the empty
vector. Ectopic expression of the HA-RanBP2(2553–2838) had
no overt effect on global sumoylation patterns as measured by
western blotting (data not shown). Importantly, overexpression
of PIASy, a SUMO E3 ligase required for sumoylation of Topo
IIa in Xenopus egg extracts (Azuma et al., 2003, 2005), did not
correct anaphase-bridge formation (Figures 4B and S6).
Complementary immunostaining experiments with antibodies
to Topo IIa and centromeres revealed that the expression of
RanBP2 SUMO E3 ligase domain in RanBP2/H cells greatly
improved the targeting of Topo IIa to inner centromeres of mi-
totic chromosomes (Figures 4C and 4D). The percentage of cells
with diffuse Topo IIa localization was reduced to only 25%
in RanBP2/H cells expressing RanBP2(2553–2838) compared
to 50% in RanBP2/H cells expressing the empty vector. No
such improvement was observed when catalytic mutants or re-
gions flanking the RanBP2 SUMO E3 ligase domain or PIASy
were overexpressed (Figures 4C and 4D). Together these data
establish a specific requirement for RanBP2 SUMOE3 ligase ac-
tivity in targeting Topo IIa protein to inner centromeres in early
mitosis to allow for decatenation of sister centromeres prior to
anaphase onset.
To investigate whether the SUMO E3 ligase domain might
exert its corrective effects by targeting Topo IIa protein, we
determined whether it formed a complex with Topo IIa in mitosis.
To this end, we expressedHA-RanBP2(2553–2838) inRanBP2+/+
MEFs and precipitated it with an antibody against HA from
mitotic extracts. As shown in Figure 4E, Topo IIa indeed coim-
munoprecipitated with HA-RanBP2(2553–2838) from these ex-
tracts. In contrast, Topo IIa failed to coimmunoprecipitate with
HA-RanBP2(1950–2553) and HA-RanBP2(2839–3224). Thus,
the SUMO E3 ligase domain of RanBP2 is sufficient for complex
formation with Topo IIa in vivo.
RanBP2 Promotes Sumoylation
of Topo IIa In Vitro and In Vivo
Next, we used an in vitro sumoylation assay to address whether
Topo IIa is a substrate for SUMOmodification by RanBP2.We in-
cubated full-length purified human Topo IIa with recombinant
SUMO E1, Ubc9, His-HA-RanBP2(2553–2838), SUMO1, and
ATP for 1 hr. Topo IIa sumoylationwas then analyzed by immuno-
blotting for Topo IIa. As shown in Figure 5A, Topo IIa was effi-
ciently sumoylated by His-HA-RanBP2(2553–2838). No such
modification occurred in the absence of His-HA-RanBP2(2553–
2838) or ATP, or when catalytic mutant His-HA-RanBP2(2553–
2838)L2651A,L2653A was used instead of His-HA-RanBP2(2553–
2838). We found that Topo IIa was also efficiently sumoylated
by His-HA-RanBP2(2553–2838) when SUMO1 was replaced by
SUMO2 or SUMO3 (Figure S7A). Collectively, these data demon-
strate that Topo IIa is a substrate of RanBP2 for SUMOmodifica-
tion in vitro.
If RanBP2 indeed functions to sumoylate Topo IIa in mitosis,
one would expect mitotic RanBP2/H MEFs to have reduced
levels of SUMO-conjugated Topo IIa. To test whether this is the
case, we stably expressed HA-tagged SUMO1 in RanBP2+/+
and RanBP2/H MEFs (Figure 5B), harvested mitotic cells by mi-
totic shake-off, and analyzed lysates prepared from these cells
for the presence of SUMO-conjugated Topo IIa by western
Figure 4. Expression of the RanBP2 SUMO E3 Ligase Domain in RanBP2-Insufficient Cells Prevents Anaphase-Bridge Formation and Topo
IIa Mislocalization
(A) Overview of the HA-tagged mutant RanBP2 proteins used in correction experiments.
(B) Incidence of chromatin bridges inRanBP2/HMEFs expressing the proteins indicated in (A) or HA-tagged PIASy. Three independent MEF lines were evaluated
per genotype (25–40 anaphases per line). Error bars indicate SEM, *p < 0.05 versus RanBP2/H MEFs carrying empty expression vector (Chi-square test).
(C) Immunolocalization of Topo IIa (green) in monastrol-treated RanBP2/H MEFs expressing the indicated proteins. Centromeres were visualized with human
ACA antibody (red). Bar = 10 mm.
(D) Quantification of prometaphases with inner centromeric versus diffuse Topo IIa localization. Seventy-five prometaphases were analyzed per genotype (three
independent MEF lines were analyzed per genotype). Error bars indicate SEM. Chart legend is as in (B). *p < 0.05 versus RanBP2/H cells carrying empty expres-
sion vectors (Chi-square test).
(E) Western blot analysis of HA immunoprecipitates from mitotic extracts of MEF cells expressing the indicated HA-RanBP2 fragments. Blots were probed for
Topo IIa.Cell 133, 103–115, April 4, 2008 ª2008 Elsevier Inc. 109
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blotting for Topo IIa. In addition tounmodifiedTopo IIa,RanBP2+/+
MEFs possessed a higher-molecular-weight SUMO1-conju-
gated Topo IIa band (Figure 5B). The presence of HA-SUMO1
in the upper band was confirmed by anti-HA immunoblotting.
SUMO1-conjugated Topo IIa was not detectable in RanBP2/H
MEFs. Importantly, expression of HA-RanBP2(2553–2838), but
not HA-RanBP2(2553–2838)L2651A,L2653A, was able to restore su-
moylation of Topo IIa in theseMEFs. To determine whether Topo
IIa sumoylation was impaired under physiological conditions,
lysates from mitotic RanBP2+/+ and RanBP2/H MEFs were
analyzed for the presence of SUMO-Topo IIa with anti-Topo IIa
antibody. As shown in Figure 5C, SUMO-modified Topo IIa was
detectable in RanBP2+/+ lysates but not in RanBP2/H lysates.
As expected, SUMO-modified Topo IIa was not observed when
RanBP2+/+ MEFs were lysed in the absence of the isopeptidase
inhibitor N-ethylmaleimide (NEM; see Figure S7B). The observa-
tion that RanBP2 hypomorphism leads to decreased sumoyla-
tion of Topo IIa in mitosis suggests that Topo IIa is an in vivo
substrate of RanBP2 during this cell-cycle stage.
To further test whether Topo IIa is the relevant target
of RanBP2 SUMO E3 ligase activity in mitosis, we expressed
a Topo IIa construct encoding a nonhydrolyzable SUMO1 in lin-
ear N-terminal fusion with Topo IIa-EGFP in RanBP2/H MEFs
and determined its ability to restore Topo IIa localization and
efficient separation of sister chromatids in these cells. SUMO1-
Topo IIa-EGFP fusion protein indeed targeted with high effi-
ciency to inner centromeres of RanBP2 hypomorphic MEFs in
mitosis (Figure 5D) and caused a dramatic reduction in ana-
phase-bridge formation in these cells (Figure 5E). These data
support the idea that the mitotic defects seen in RanBP2
hypomorphic cells are due to impaired SUMO modification of
Topo IIa.
Depletion of PIASy in Xenopus egg extracts or HeLa cells has
been shown to inhibit Topo IIa targeting to inner centromeresand block chromosome segregation (Azuma et al., 2003, 2005;
Diaz-Martinez et al., 2006), suggesting that RanBP2 and PIASy
E3 ligases might have overlapping functions in mitosis. To inves-
tigate this, we analyzed the subcellular localization of Topo IIa in
MEFs derived from PIASy/ mice (Roth et al., 2004). As shown
in Figure 5F, PIASy loss had no impact on Topo IIa targeting to
inner centromeres in mitosis. MEFs from an independently gen-
erated PIASy/ mouse strain yielded the same results (Wong
et al., 2004) (data not shown). Furthermore, anaphase-bridge
frequencies and aneuploidy were not significantly elevated in
PIASy/ MEFs (Figures 5G and S8). Western blot analysis of
mitotic lysates from PIASy+/+ and PIASy/ MEFs for Topo IIa
revealed that SUMO modification of Topo IIa was unperturbed
by the deletion of PIASy (Figure 5H). These data demonstrate
that, at least in MEFs, RanBP2 rather than PIASy regulates accu-
mulation of Topo IIa at inner centromeres and proper chromo-
some segregation.
RanBP2 Insufficient Mice Are Prone
to Carcinogen-Induced and Spontaneous Tumors
As RanBP2 insufficiency leads to chromosome number instabil-
ity, a condition that has been linked to cancer development, we
sought to determine whether mice with reduced RanBP2 ex-
pression are prone to tumorigenesis. To this end, we performed
a tumor bioassay with 7,12-dimethylbenz[a]anthracene (DMBA),
a carcinogen that predisposes wild-type mice to lung tumors,
skin tumors, and thymic lymphomas when applied to the skin
(Serrano et al., 1996). Pups from RanBP2H/H 3 RanBP2/H and
RanBP2+/3 RanBP2+/H intercrosses were given a single appli-
cation of 50 ml 0.5%DMBA to the dorsal surface on postnatal day
5. Treated animals were thenmonitored for development of overt
tumors over a period of 5 months. The incidence of skin tumors
was dramatically increased in RanBP2H/H and RanBP2/H mice
compared to RanBP2+/+, RanBP2+/H, and RanBP2+/ miceFigure 5. RanBP2 Sumoylates Topo IIa in Mitosis
(A) In vitro sumoylation of Topo IIa by the RanBP2 E3 ligase domain. Twenty nanograms of recombinant human Topo IIawas tested for SUMO1modification in the
presence or absence of 100 ng wild-type (His-HA-RanBP2[2553–2838]) or mutant (His-HA-RanBP2[2553–2838]L2651A,L2653A) RanBP2 SUMO E3 ligase domain,
110 ng E1, 50 ng Ubc9, 5 mg SUMO1, and 1 mM ATP. Samples were incubated at 37C for 1 hr and then analyzed by western blotting with antibody to Topo IIa.
(B) In vivo sumoylation of Topo IIa by RanBP2. Mitotic shake-off lysates from RanBP2+/+ and RanBP2/HMEFs containing the indicated expression vectors were
prepared and analyzed by western blotting for Topo IIa and HA. P-H3 and actin antibodies were used to verify that similar amounts of mitotic cells and protein
were present in lysates used.
(C) RanBP2 sumoylation of Topo IIa under physiological conditions. Mitotic shake-off lysates were prepared fromRanBP2+/+ andRanBP2/HMEFs and analyzed
by western blotting for Topo IIa. P-H3 and actin antibodies were used to ensure that lysates contained similar amounts of mitotic cells and protein.
(D) Localization of SUMO1-Topo IIa-EGFP in RanBP2/H MEFs during prometaphase. (Left) Confocal image of a prometaphase expressing SUMO1-Topo
IIa-EGFP. Centromeres were visualized by immunostaining with ACA antibody. Bar = 5 mm. (Right) Quantification of cells with inner centromeric versus diffuse
localization of SUMO1-Topo IIa-EGFP during prometaphase. Two independent RanBP2/H MEF lines were analyzed (50 prometaphases per line). Error bars
indicate SEM, *p < 0.05 versus untransfected RanBP2/H MEFs (paired t test). Localization of Topo IIa in untransfected RanBP2/H MEFs was determined by
immunostaining for Topo IIa and centromeres as in Figure 3C.
(E) Incidence of chromatin bridges in RanBP2/H MEFs in the absence or presence of SUMO1-Topo IIa-EGFP. Two independent RanBP2/H MEF lines were
analyzed (50 prometaphases per line). Error bars indicate SEM, *p < 0.05 versus RanBP2/H untransfected MEFs (paired t test).
(F) Immunolocalization of Topo IIa in PIASy/ MEFs during prometaphase. (Left) Confocal image of a PIASy/ MEF immunostained for Topo IIa and centro-
meres. Bar = 5 mm. (Right) Quantification of PIASy+/+ and PIASy/ prometaphases with inner centromeric versus diffuse localization of Topo IIa. Three indepen-
dent MEF lines were analyzed (25–50 prometaphases per line). Error bars indicate SEM.
(G) Incidence of chromatin bridges inPIASy/MEFs examined by live-cell imaging. Three independentPIASy+/+ andPIASy/MEF lines were analyzed (25–40
anaphases per line). Error bars indicate SEM.
(H) Sumoylation of endogenous Topo IIa in PIASy/ MEFs. Experimental details were as in (C).
(I) Proposedmodel for the role of RanBP2 in sister-chromosome separation. Inmitosis, RanBP2 (in conjunctionwith Ubc9) binds to and sumoylates Topo IIa in the
mitotic cytosol. This modification serves as a signal for Topo IIa targeting to inner centromeres, where it functions to decatenate sister centromeres, thus allowing
for proper separation of sister chromosomes in anaphase. As SUMO-modified Topo IIa represents only a small fraction of the total Topo IIa pool (Figure 5C),
SUMO conjugation may only be required for initial targeting of Topo IIa to centromeres but not for maintenance of centromeric localization.Cell 133, 103–115, April 4, 2008 ª2008 Elsevier Inc. 111
(Figures 6A and 6B). Seventy-seven percent of RanBP2/H and
60% of RanBP2H/H mice developed skin tumors compared to
31% of RanBP2+/, 24% of RanBP2+/H, and 13% of wild-type
mice. Moreover, the latency with which skin tumors formed
was much shorter in RanBP2H/H and RanBP2/H mice than in
RanBP2+/+, RanBP2+/H, and RanBP2+/ mice (Figure 6B). Com-
pared with RanBP2+/+ mice, the skin tumor burden was 16- and
23-fold increased in RanBP2H/H and RanBP2/H mice, respec-
tively (Figure 6C). In RanBP2+/ and RanBP2+/H mice this in-
crease was only 3-fold. At 5 months of age, the animals were
sacrificed and their internal organs were screened for tumors.
Figure 6. RanBP2 Suppresses Spontaneous
and DMBA-Induced Tumorigenesis
(A) Gross appearance (top) and histology (bottom)
of skin tumor of a DMBA-treated RanBP2/H
mouse.
(B) Skin tumor incidence of DMBA-treated mice of
the indicated genotypes. *p < 0.05 versus wild-
type mice (Log rank test).
(C) Skin tumor burden of DMBA-treated mice of
the indicated genotypes. Error bars indicate
SEM, *p < 0.05 versus wild-type mice (Mann
Whitney test).
(D) Gross appearance (top) and histology (bottom)
of lung tumors of a DMBA-treated RanBP2/H
mouse.
(E) Lung tumor incidence of DMBA-treatedmice of
the indicated genotypes. Error bars indicate SEM,
*p < 0.05 versus wild-type mice (Chi-square test).
(F) Lung tumor burden of DMBA-treated mice of
the indicated genotypes. Error bars indicate
SEM, *p < 0.05 versus wild-type mice (Mann
Whitney test).
(G) Tumor-free survival of RanBP2+/+, RanBP2H/H,
and RanBP2/H mice. *p < 0.01 versus wild-type
mice (Log rank test).
(H) Tumor spectrum of mice with various RanBP2
genotypes.
(I) Gross images and histological analysis of repre-
sentative spontaneous tumors from RanBP2/H
mice.
(J) Chromosome counts on primary tumors of
RanBP2H/H and RanBP2/H mice.
Lung tumors were identified in 58% of
RanBP2+/+ mice (Figures 6D and 6E).
Small increases in the incidence of lung
tumorigenesis were observed in
RanBP2+/ and RanBP2+/H mice, but
they were not statistically significant. In
contrast, the increases in lung tumor inci-
dence were much larger in RanBP2H/H
and RanBP2/H animals, with 95% of
RanBP2H/H and 100% of RanBP2/H ani-
mals having this tumor type. Similarly,
the lung tumor burden in RanBP2H/H and
RanBP2/Hmice was considerably higher
than in RanBP2+/, RanBP2+/H, and
RanBP2+/+ mice, with RanBP2H/H and
RanBP2/H animals developing on aver-
age 17 and 14 tumors per mouse, respectively, compared to
three or less in the other genotypes (Figure 6F).
Furthermore, to determine if RanBP2 insufficiency promotes
spontaneous tumorigenesis, cohorts of RanBP2+/+, RanBP2H/H,
and RanBP2/H mice were established and monitored biweekly
for signs of overt tumors or ill health for up to 2 years. Moribund
animals were sacrificed and screened for tumors. Tumors were
collected and embedded in paraffin for histopathology.
RanBP2/H and RanBP2H/H mice formed tumors with increased
incidence and shorter latency than RanBP2+/+ mice (Figure 6G).
Lung adenocarcinomas were the most prevalent tumor type in112 Cell 133, 103–115, April 4, 2008 ª2008 Elsevier Inc.
RanBP2/H and RanBP2H/H mice (Figures 6H and 6I). Other fre-
quently observed tumor types in these mice were hepatocellular
carcinomas and sarcomas. Chromosome counts and interphase
fluorescence in situ hybridization (FISH) using probes for
chromosomes 4, 7, 9, and 12 demonstrated that tumors of all
three types consistently displayed severe aneuploidy (Figures
6J and S9). Thus, when RanBP2 expression drops below a crit-
ical threshold level, mice become prone to spontaneous and
carcinogen-induced tumorigenesis. Furthermore, these studies
establish RanBP2 as a protein with tumor-suppressive activity
and reveal a correlation between aneuploidy and tumorigenesis.
DISCUSSION
RanBP2 has been implicated in both nucleocytoplasmic trans-
port and mitosis and is unique among nucleoporins in that it is
a SUMO E3 ligase. However, the critical biological functions of
RanBP2 and the in vivo targets of its ligase activity have been un-
known. Progress in understanding the physiological functions of
mammalian nucleoporins has been hampered by the fact that
most loss-of-function mutations disrupt early embryogenesis
so severely that the embryo dies. One way around this problem
is to study hypomorphic mutant mice. Using this approach, we
established a requirement for RanBP2 in maintenance of chro-
mosome number stability and suppression of tumorigenesis.
The observation that the mitotic phenotype caused by RanBP2
hypomorphism is reminiscent of Topo IIa inhibition led to the
discovery that RanBP2 regulation of chromosome segregation
fidelity is mediated, at least in part, by the sumoylation of Topo
IIa in mitosis.
RanBP2 Sumoylates Topo IIa
to Mediate Sister-Chromatid Separation
Siz1p and Siz2p, two proteins that provide the major SUMO
(Smt3p) E3 ligase activity in budding yeast, execute SUMOmod-
ification of Top2p in mitosis (Takahashi et al., 2006). This modifi-
cation seems to function as a signal for Top2p targeting to
pericentromeric regions of mitotic chromosomes. Seven obser-
vations reported here suggest that, in mammals, RanBP2 cata-
lyzes the SUMO modification of Topo IIa in mitosis to direct this
protein to inner centromeres for accurate chromosome separa-
tion prior to anaphase onset (Figure 5I). First, catalytic inhibition
of Topo IIa causes formation of chromatin bridges in anaphase
due to incomplete DNA decatenation (Clarke et al., 1993). Ana-
phase-bridge formation is the primary phenotype of RanBP2
hypomorphic cells. Second, the RanBP2 hypomorphic cells fail
to accumulate Topo IIa at inner centromeres of mitotic chromo-
somes at high incidence. Third, ectopic expression of the
RanBP2 SUMO E3 ligase domain in RanBP2 hypomorphic cells
by itself is sufficient to restore proper localization of Topo IIa to in-
ner centromeres and prevent anaphase-bridge formation. These
corrective effects require SUMO conjugation, as they were not
observed in RanBP2 hypomorphic cells expressing catalytic
mutants of the RanBP2 E3 ligase domain. Unlike Topo IIa, the
RanBP2 SUMO E3 ligase domain and full-length RanBP2 do
not concentrate at inner centromeres of mitotic chromosomes,
suggesting that Topo IIa is sumoylated by RanBP2 in the mitotic
cytosol and, from there, translocates to inner centromeres ofduplicated chromosomes without RanBP2 (Figure 5I). Fourth,
RanBP2 forms a complex with Topo IIa specifically in mitosis.
Importantly, the abundance of RanBP2-Topo IIa complexes is
substantially reduced in RanBP2 hypomorphic cells. Fifth, the
RanBP2 SUMO E3 ligase domain, which is sufficient for Topo
IIa binding, efficiently catalyzes SUMO conjugation of Topo IIa
in an in vitro assay using recombinant proteins. We show that
Topo IIa can bemodified by all three SUMOspecies in this assay.
Sixth, RanBP2 hypomorphic cells have substantially lower levels
of SUMO-modified Topo IIa than cells expressing a full comple-
ment ofRanBP2. Furthermore, ectopic expressionof theRanBP2
SUMO E3 ligase domain in RanBP2 hypomorphic cells is suffi-
cient to restore SUMO conjugation of Topo IIa in mitosis. Sev-
enth, ectopically expressed SUMO1-Topo IIa fusion protein cor-
rects both Topo IIa mislocalization and anaphase-bridge
formation in RanBP2 hypomorphic MEFs. As expression of the
catalytically active SUMOE3 ligase domain has similar corrective
effects in these cells, it is reasonable to conclude that Topo IIa is
the relevant substrate of RanBP2 in mitosis.
Previous studies in Xenopus egg extracts have implicated
PIASy in the sumoylation of Topo IIa (Azuma et al., 2003, 2005).
This combined with the observation that depletion of PIASy
from these extracts results inmetaphase arrest led to speculation
that sumoylation of Topo IIa is essential for sister-chromatid sep-
aration in mitosis. The observation that siRNA-mediated deple-
tion of PIASy from HeLa cells interferes with targeting of Topo
IIa and blocks separation of duplicated chromosomes further
supported this idea (Diaz-Martinez et al., 2006). However, here
we demonstrate that Topo IIa sumoylation, Topo IIa accumula-
tion at inner centromeres, and proper separation of sister
chromosomes are unperturbed in PIASy/ MEFs. Consistent
with this,PIASy/mice are viable, fertile, anddevoid of anyovert
phenotypes (Roth et al., 2004; Wong et al., 2004). Furthermore,
PIASy overexpression was found to be unable to correct Topo
IIa mislocalization and chromosome missegregation in RanBP2
hypomorphic MEFs. One interpretation is that the role of
RanBP2 and PIASy in Topo IIa sumoylation is species, cell
type, and/or transformation status dependent. It is also possible
that off-target effects of siRNA oligos drive aberrant Topo IIa
localization and chromosome segregation in the PIASy-depleted
HeLa cells. Furthermore, it is unknown whether depletion of
PIASy in HeLa cells correlates with impaired SUMOmodification
of Topo IIa.
RanBP2 in Chromosomal Instability and Tumorigenesis
Our finding that RanBP2 hypomorphic mice are highly suscepti-
ble to carcinogen-induced tumors and prone to various sponta-
neous tumors reveals a novel and important role for RanBP2 in
suppression of tumorigenesis. What could be the tumor-sup-
pressive function(s) of RanBP2? Given that RanBP2 hypomor-
phism induces aneuploidy and that the incidence of aneuploidy
is high in human cancers, it is tempting to speculate that RanBP2
exerts its tumor-suppressive effect by ensuring accurate segre-
gation of duplicated chromosomes in mitosis. The finding that
aneuploidy is high in tumors from RanBP2 hypomorphic mice
supports this notion. Yet, whether aneuploidy is causally impli-
cated in cancer development has been a subject of intense
investigation and debate. Recent studies of mutant mouseCell 133, 103–115, April 4, 2008 ª2008 Elsevier Inc. 113
strains with defects in mitotic checkpoint genes that increase the
incidence of missegregation of whole chromosomes suggest
that aneuploidy indeed has the ability to promote tumorigenesis
(Weaver and Cleveland, 2006). Structural chromosome defects
have also been implicated in tumor development. Despite having
high rates of chromatin-bridge formation, RanBP2 hypomorphic
MEFs showed no evidence of increased gross chromosomal
aberrations. However, this does not exclude the possibility that
structural chromosome damage from improper decatenation
contributes to tumor development in RanBP2 mutant mice. For
instance, it is possible that transformed cells may be more resis-
tant to cell death induced by structural damage than nontrans-
formed cells.
AlthoughRanBP2 isawell-establishedcomponentof themam-
malian NPC, cells that are hypomorphic for this protein displayed
no overt defects in NLS-dependent protein import, NES-depen-
dent protein export, or mRNA export. These findings suggest
that tumor development in RanBP2 hypomorphicmice is unlikely
due to impairments in some of the major transport pathways.
However, it cannot be excluded that specific NLS- or NES-con-
taining proteins that are important for controlled cell proliferation
or induction of apoptosis are expressed at inappropriate levels
or unable to reach their intracellular sites of action in RanBP2
hypomorphic mice. Moreover, only those transport pathways
thatwere functionally impairedbyRanBP2depletion inHeLacells
were included in our analysis (Bernad et al., 2004; Hutten and
Kehlenbach, 2006). Thus, it ispossible that certain transport path-
ways are not optimally functioning in RanBP2 hypomorphic cells.
To explore whether RanBP2 might have a role in human can-
cer, we compared the relative expression of RanBP2 in normal
tissue versus tumors using human gene expression data from
the Oncomine database (http://www.oncomine.com). RanBP2
hypomorphic mice are particularly sensitive to spontaneous
and carcinogen-induced lung tumors. Consistent with these
data, two independent studies revealed that RanBP2 transcript
levels are substantially reduced in human non-small cell lung
cancers (Beer et al., 2002; Garber et al., 2001). These findings,
along with data showing that RanBP2 expression is frequently
downregulated in human lung cancer cell lines and primary
lung tumor samples (D. Baker and J.M.v.D., unpublished data),
suggest that RanBP2 downregulation is a frequent event in
human lung tumorigenesis.
EXPERIMENTAL PROCEDURES
Generation of Hypomorphic and Knockout Mice
and Tumor Susceptibility Studies
The gene targeting procedure used to generate the hypomorphic RanBP2 al-
lele (H) was as previously described (Dawlaty and van Deursen, 2006). Cor-
rectly targeted ES cell clones were injected into blastocysts and RanBP2+/H
offspring were obtained from the resulting chimeras through standard proce-
dures.RanBP2+/micewere established byCre-mediated excision ofRanBP2
exon 3 in the female germline by the use of MMTV-Cre transgenic mice (this
excision causes out-of-frame fusion of exons 2 and 4). All mice were main-
tained on a 129Sv/E 3 C57BL/6 genetic background. Mice in tumor suscepti-
bility studies were monitored daily. Moribund mice were killed and their major
organs screened for overt tumors. Tumors were processed for histopathology
by standard procedures. Prism software was used for the generation of tumor-
free survival curves and for statistical analyses. DMBA treatment was as
described (Serrano et al., 1996).114 Cell 133, 103–115, April 4, 2008 ª2008 Elsevier Inc.Western Blotting and Coimmunoprecipitation
Western blot analyses and coimmunoprecipitations were essentially done as
described (Kasper et al., 1999). Lysis buffer for detection of SUMO-modified
Topo IIa by western blotting consisted of 50 mM Tris HCl (pH 7.5), 150 mM
NaCl, 0.1% NP40, 0.5% SDS, protease inhibitor cocktail (Roche, Cat. #11-
836-170-001), and 20 mM NEM. Samples were kept on ice for 15 min and
vortexed at 2 min intervals and then boiled in Laemmli buffer. Antibodies
were rabbit anti-hRanBP2(2500–3224) and rabbit anti-hRanBP2(2550–2837)
(Joseph et al., 2004); rabbit anti-Topo IIa (Topogen); mouse anti-b-actin (AC-
151, Sigma); rat anti-HA (3F10; Roche); and mouse anti-phosphohistone H3
(Ser10) (Upstate).
Indirect Immunofluorescence and Live-Cell Imaging
MEFswere cultured on 10-well glass slides for 24 hr, arrested in prometaphase
with 100 mMmonastrol for 3 hr, and fixedwith 3%paraformaldehyde in PBS for
12 min. Antibody incubations were as described (Kasper et al., 1999). Anti-
bodies were rabbit anti-Topo IIa (Topogen); human anti-centromeric antibody
(Antibodies Incorporated); rabbit anti-Mad1 (Dr. T. Yen); and rabbit anti-Cenp-
E (Dr. D. Cleveland). Live-cell imaging was performed as described (Jegana-
than et al., 2005).
In Vitro Sumoylation Assays
Sumoylation reactions were carried out in a total volume of 20 ml. Reactions
contained 50 mM HEPES (pH 8), 100 mM NaCl, 1 mM DTT, 1 mM Mg-ATP,
50 nM E1 (110 ng), 25 mM SUMO1, 2, or 3 (5 mg), 125 nM Ubc9 (50 ng),
100 ng recombinant His-HA-RanBP2(2553–2838) or His-HA-RanBP2(2553–
2838)L2651A,L2653A, and 20 ng of purified full-length Topo IIa (Topogen). Reac-
tions were performed at 37C for 1 hr, stopped with equal volume of 23
Laemmli buffer, resolved by SDS-PAGE on 5% Tris-HCl gels, and analyzed
by immunoblotting for Topo IIa. Recombinant E1, Ubc9, and SUMO1–3 were
from Boston Biochem (SUMO1 conjugation kit; Cat. #K-710). To produce re-
combinant RanBP2 His-HA-RanBP2(2553–2838) and His-HA-RanBP2(2553–
2838)L2651A,L2653A, their corresponding cDNA constructs were cloned into
BamH1 and Xho1 sites of pET28a(+) (Novagen). Proteins tagged with His
were expressed in BL21 (DE3) bacteria at 15C and purified from bacterial
lysates with Ni2+ agarose.
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